Princeton Global Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Princeton Global Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,500	Closed	-$46K	–	624
2022 Q4	$46K	Hold	2,500	–	–	0.01%	246
2022 Q3	$68K	Buy	+2,500	New	+$50.7K	0.02%	215

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Princeton Global Asset Management's RVNC Position: Q1 2023 in Review

Princeton Global Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2023, closing a stake of 2,500 shares — an estimated $46K sold.

Princeton Global Asset Management first reported a position in RVNC in Q3 2022 and held it in 2 quarters. The position peaked at $68K in Q3 2022. 216 funds tracked by Wall St. Rank hold RVNC as of Q1 2023.

Princeton Global Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
Princeton Global Asset Management sold 2,500 Revance Therapeutics, Inc. shares in Q1 2023, an estimated $46K.
Princeton Global Asset Management first reported a position in Revance Therapeutics, Inc. in Q3 2022 and held it in 2 quarters.
Princeton Global Asset Management's Revance Therapeutics, Inc. position peaked at $68K in Q3 2022.
216 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2023.

Based on Princeton Global Asset Management's 13F filing for Q1 2023, filed 20 Apr 2023.